University Research Highlights — 2026-03-26
This week's university research roundup covers a major protein breakthrough with implications for Parkinson's disease treatment, new findings on the link between a common pesticide and Parkinson's risk, and a promising study on fatty liver disease. Fresh findings from institutions across Asia, Europe, and North America push science forward in medicine, neuroscience, and AI reliability.
University Research Highlights — 2026-03-26
Headline Breakthroughs
Zhejiang University Pioneers Membrane Protein Breakthrough Linked to Parkinson's Disease
- University / Institution: Zhejiang University (Hangzhou, China)
- Published in: Not specified in source
- The Discovery: A multidisciplinary team at Zhejiang University has made a significant breakthrough in understanding membrane proteins — specifically those implicated in Parkinson's disease and other genetic afflictions. The research opens new avenues for understanding how these proteins function and malfunction at the cellular level.
- Why It Matters: Membrane protein dysfunction is at the heart of several neurodegenerative diseases. A better structural and functional understanding of these proteins could accelerate drug development targeting Parkinson's disease and related conditions, potentially benefiting millions of patients worldwide.
- What's Next: Researchers are expected to leverage these findings to explore targeted therapeutic strategies for Parkinson's disease and other conditions caused by membrane protein dysregulation.
Fatty Liver Breakthrough: MicroRNA-93 Identified as Central Regulator in MASLD
- University / Institution: Ulsan University Hospital (UUH), South Korea, in collaboration with an international research team
- Published in: Not specified in source
- The Discovery: Researchers led by Prof. Neung Hwa Park at Ulsan University Hospital identified microRNA-93 (miR-93) as a central regulator in metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease. The team also found that a common vitamin shows promise in modulating this pathway.
- Why It Matters: MASLD is one of the most prevalent liver conditions globally, affecting hundreds of millions of people, with no approved drug treatments in many markets. Identifying miR-93 as a regulator provides a concrete molecular target and potentially a low-cost intervention using an already-available vitamin supplement.
- What's Next: The research team is expected to move toward preclinical validation and explore which specific vitamin formulations most effectively modulate miR-93 activity in liver tissue.
Top Science News -- ScienceDaily
sciencedaily.com
Health & Medicine News -- ScienceDaily
Fatty liver breakthrough: A common vitamin shows promise | ScienceDaily
Study finds ChatGPT gets science wrong more often than you think | ScienceDaily
Fatty liver breakthrough: A common vitamin shows promise | ScienceDaily
Common pesticide may more than double Parkinson’s disease risk | ScienceDaily
Scientists warn fake research is spreading faster than real science | ScienceDaily
Brain's Navigational System Mapped by Neuroscientist Prof. Christian Doeller
- University / Institution: Research institution of Prof. Christian Doeller (Germany); recognized with the Leibniz Prize
- Published in: Not specified in source
- The Discovery: Neuroscientist Prof. Christian Doeller has been awarded the prestigious Leibniz Prize (worth 2.5 million euros) for his groundbreaking research revealing that the brain functions as an internal navigational system — not just for physical space, but for conceptual and cognitive space as well. His work maps how the brain encodes spatial and non-spatial information using the same navigational architecture.
- Why It Matters: Understanding the brain's navigational mechanisms has profound implications for treating conditions like Alzheimer's disease, where spatial disorientation is an early symptom. It also opens new paths for understanding memory, learning, and cognitive decline.
- What's Next: Prof. Doeller's 2.5 million euro Leibniz Prize funding will support expanded research into how the brain's navigational system underpins broader cognitive functions.
Medical & Health Research
- Common Pesticide May More Than Double Parkinson's Disease Risk — UCLA Health: A new UCLA Health study found that people living in areas with sustained exposure to a common pesticide had more than 2.5 times the likelihood of developing Parkinson's disease. The findings add to a growing body of evidence linking agricultural chemical exposure to neurodegeneration.
-
What Happens After Stopping Ozempic — Real-World Data Reassures — ScienceDaily: A large real-world study of nearly 8,000 patients found that most people who discontinue GLP-1 weight-loss drugs like Ozempic or Mounjaro manage to maintain their weight loss — or continue losing weight — by restarting treatment or through lifestyle adjustments, countering fears of dramatic rebound weight gain.
-
Duke Researchers Develop New Model to Accelerate Medical Discovery — Duke University: Clinical studies typically take up to a decade, but Duke researchers are advancing a new approach that leverages existing health data to dramatically speed up the process of finding answers, reducing the need for costly and time-consuming prospective trials.
- Oxford & Interna Therapeutics Launch Intranasal siRNA COVID-19 Prevention Trial — University of Oxford: Interna Therapeutics has signed a human challenge trial agreement with the University of Oxford to advance an intranasal MNM-siRNA program targeting SARS-CoV-2 as a prophylaxis (preventive treatment), representing a novel RNA-based approach to pandemic preparedness.
Top Science News -- ScienceDaily
sciencedaily.com
Health & Medicine News -- ScienceDaily
Fatty liver breakthrough: A common vitamin shows promise | ScienceDaily
Study finds ChatGPT gets science wrong more often than you think | ScienceDaily
Fatty liver breakthrough: A common vitamin shows promise | ScienceDaily
Common pesticide may more than double Parkinson’s disease risk | ScienceDaily
Scientists warn fake research is spreading faster than real science | ScienceDaily
Technology & Engineering
- ChatGPT Gets Science Wrong More Often Than You Think — ScienceDaily: A new study put ChatGPT to the test by asking it to evaluate whether hundreds of scientific hypotheses were true or false. While the AI achieved roughly 80% surface-level accuracy, deeper analysis revealed significant gaps in its reliability for scientific reasoning, raising concerns about AI use in research workflows.
- 2026 Young Chemist Award: Breakthrough PFAS Monitoring and Treatment Research — Metrohm USA (award recipient: Sarah Ortbal): Researcher Sarah Ortbal won the 2026 Young Chemist Award for work addressing PFAS ("forever chemicals") contamination at multiple critical environmental points — including wastewater treatment and surface waters — using both targeted PFAS methods and adsorbable organic fluorine (AOF) analysis to capture the broader fluorinated organic load that conventional methods miss.
Top Science News -- ScienceDaily
sciencedaily.com
Health & Medicine News -- ScienceDaily
Fatty liver breakthrough: A common vitamin shows promise | ScienceDaily
Study finds ChatGPT gets science wrong more often than you think | ScienceDaily
Fatty liver breakthrough: A common vitamin shows promise | ScienceDaily
Common pesticide may more than double Parkinson’s disease risk | ScienceDaily
Scientists warn fake research is spreading faster than real science | ScienceDaily
Climate & Environment
No recent data available for this section that falls within the verified 7-day coverage window (after 2026-03-19) based on available sources.
What to Watch Next
- Neurology trial readouts in H1 2026: Multiple key neurology clinical trials are expected to report results in the first half of 2026. Researchers and clinicians following Alzheimer's, Parkinson's, and related conditions should monitor NeurologyLive's curated tracker for upcoming data.
- Glomerular disease therapies advancing: The Clinical Trial Summit 2026 outlined an ambitious near-term vision for glomerular disease treatment including new clinical endpoints, combination therapies, and gene therapy — expect trial updates in the coming months.
- AI reliability in science: The finding that ChatGPT scores only ~80% on scientific hypothesis evaluation will likely trigger a wave of follow-up research testing other large language models across disciplines. Watch for replication studies and proposed verification frameworks targeting AI use in peer review and hypothesis generation.
Reader Action Items
- Read in full: The ScienceDaily report on miR-93 as a regulator of fatty liver disease (MASLD) — a compact but significant finding with near-term therapeutic implications.
- Access this resource: The Duke University Office of Interdisciplinary Programs is developing new data-leveraging frameworks for accelerating clinical research — worth monitoring for publicly available tools and datasets.
- Follow this debate: How reliable is AI for scientific reasoning? This week's ChatGPT hypothesis-evaluation study opens a critical question for the research community: should journals and institutions implement AI-verification standards before researchers use LLMs in literature review or hypothesis testing?
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Create your own signal
Describe what you want to know, and AI will curate it for you automatically.
Create SignalPowered by
